Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 6.9x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 12 Jun 2026	US$1.2t	US$170.0b	-US$12,156,213,059.82	16.5x	-102.2x	7.3x
Sun, 10 May 2026	US$1.3t	US$170.4b	-US$11,735,587,251.14	17.7x	-110.3x	7.6x
Tue, 07 Apr 2026	US$1.3t	US$166.1b	-US$11,844,065,571.08	16.2x	-108.8x	7.8x
Thu, 05 Mar 2026	US$1.3t	US$169.6b	-US$13,987,007,729.05	21.6x	-94.4x	7.8x
Sat, 31 Jan 2026	US$1.3t	US$163.5b	-US$15,009,663,548.11	20.3x	-84.3x	7.7x
Mon, 29 Dec 2025	US$1.2t	US$163.6b	-US$15,776,614,106.35	22x	-78.8x	7.6x
Wed, 26 Nov 2025	US$1.2t	US$163.3b	-US$16,349,343,940.48	18.8x	-74.6x	7.5x
Fri, 24 Oct 2025	US$1.2t	US$163.4b	-US$18,379,211,811.07	17x	-63.3x	7.1x
Sun, 21 Sep 2025	US$1.1t	US$163.5b	-US$18,307,901,758.97	16.3x	-59.2x	6.6x
Tue, 19 Aug 2025	US$1.1t	US$163.6b	-US$18,805,727,983.06	15.6x	-57.2x	6.6x
Thu, 17 Jul 2025	US$964.8b	US$155.8b	-US$23,409,909,784.69	17.2x	-41.2x	6.2x
Sat, 14 Jun 2025	US$958.5b	US$155.9b	-US$23,959,805,126.31	16.3x	-40x	6.1x
Mon, 12 May 2025	US$861.1b	US$154.9b	-US$24,538,327,634.73	16.7x	-35.1x	5.6x
Wed, 09 Apr 2025	US$728.1b	US$118.6b	-US$36,894,652,377.23	19.3x	-19.7x	6.1x
Fri, 07 Mar 2025	US$848.3b	US$119.0b	-US$37,227,382,606.31	16.9x	-22.8x	7.1x
Sun, 02 Feb 2025	US$1.0t	US$149.5b	-US$26,306,804,829.57	17.2x	-38.1x	6.7x
Tue, 31 Dec 2024	US$977.8b	US$149.6b	-US$26,368,249,096.05	16.9x	-37.1x	6.5x
Thu, 28 Nov 2024	US$1.0t	US$150.0b	-US$26,605,248,182.60	16.6x	-38.7x	6.9x
Sat, 26 Oct 2024	US$886.8b	US$113.1b	-US$36,035,376,152.30	20.6x	-24.6x	7.8x
Mon, 23 Sep 2024	US$920.0b	US$113.2b	-US$35,983,947,157.41	21.9x	-25.6x	8.1x
Wed, 21 Aug 2024	US$905.2b	US$113.2b	-US$35,832,221,284.65	22.9x	-25.3x	8x
Fri, 19 Jul 2024	US$1.2t	US$164.5b	-US$28,050,002,699.28	29x	-43.2x	7.4x
Sun, 16 Jun 2024	US$1.2t	US$164.4b	-US$28,071,754,707.37	27.3x	-41.2x	7x
Tue, 14 May 2024	US$1.1t	US$164.7b	-US$26,999,224,352.94	23.2x	-41.7x	6.8x
Thu, 11 Apr 2024	US$1.1t	US$164.3b	-US$23,371,324,513.62	21.4x	-48.7x	6.9x
Sat, 09 Mar 2024	US$1.2t	US$167.3b	-US$22,121,973,439.03	19x	-54x	7.1x
Mon, 05 Feb 2024	US$1.4t	US$203.9b	-US$24,425,425,728.00	19.2x	-58.9x	7.1x
Wed, 03 Jan 2024	US$1.4t	US$204.8b	-US$22,201,360,571.00	21x	-63.9x	6.9x
Fri, 01 Dec 2023	US$1.2t	US$204.7b	-US$22,039,871,274.00	18.5x	-56x	6x
Sun, 29 Oct 2023	US$1.2t	US$206.6b	-US$15,166,070,486.00	16.3x	-77.7x	5.7x
Tue, 26 Sep 2023	US$1.3t	US$207.4b	-US$12,899,236,949.00	17x	-97.7x	6.1x
Thu, 24 Aug 2023	US$1.3t	US$207.6b	-US$12,449,828,498.00	17.5x	-103.1x	6.2x
Sat, 22 Jul 2023	US$1.2t	US$186.5b	-US$16,009,709,300.00	12.8x	-72x	6.2x
Mon, 19 Jun 2023	US$1.2t	US$186.3b	-US$16,034,836,469.00	12.1x	-72.3x	6.2x


US Market	-2.36%
Healthcare	0.99%
Biotech	-0.93%
Biotech	-0.93%

Company	Last Price	7D	1Y	Valuation
AMGN Amgen	US$355.18	1.6% +US$3.0b	20.3%	PE24.6x
NUVL Nuvalent	US$123.25	35.5% +US$2.6b	57.5%	PB8.3x
TGTX TG Therapeutics	US$49.52	23.3% +US$1.3b	37.5%	PE15.2x
INCY Incyte	US$108.53	6.0% +US$1.2b	60.2%	PE15.1x
TNGX Tango Therapeutics	US$29.82	34.6% +US$1.1b	490.5%	PS75.7x

Announcement • 3h

Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions

Vertex Pharmaceuticals Incorporated announced data demonstrating the clinical benefits of CASGEVY (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). Data from an interim analysis of the CLIMB-151 and CLIMB-141 studies highlight the transformative potential CASGEVY can provide to children ages 5–11 and are consistent with the durable clinical profile established in adult and adolescent patients. Collectively, these findings highlight the potential benefits of addressing vaso-occlusive crises (VOCs) and transfusion burden earlier in life, which can begin in childhood and are associated with cumulative, long-term complications in SCD and TDT including organ damage. In the Phase 3 CLIMB-151 clinical study of children with severe SCD, all 11 patients dosed are free from VOCs and all 8 out of 8 (100%) patients with sufficient follow-up achieved the primary endpoint of being free from VOCs for at least 12 consecutive months (VF12). Of children achieving VF12, the mean (min, max) duration VOC-free was 19.0 (13.2, 30.1) months. In the Phase 3 CLIMB-141 clinical study of children with TDT, 15 patients have been dosed with CASGEVY, and all 8 out of 8 (100%) patients with sufficient follow-up achieved the primary endpoint of transfusion independence for at least 12 consecutive months while maintaining a weighted average hemoglobin of at least 9 g/dL (TI12). All children who achieved TI12 remained so throughout the follow-up; the mean (min, max) duration transfusion independence was 23.4 (13.3, 28.5) months. The safety profile of CASGEVY in younger patients is consistent with myeloablative conditioning and autologous transplant, as established in clinical studies in older patients with SCD and TDT. As previously disclosed, there was one death, not related to CASGEVY, in a child with TDT who developed severe veno-occlusive disease from busulfan conditioning. Consistent with studies in older patients, children with severe SCD and TDT treated with CASGEVY have durable and clinically relevant increases in fetal hemoglobin (HbF) and stable allelic editing. CASGEVY is currently approved for eligible people 12 years and older with SCD with recurrent VOCs or TDT in several countries around the world. In the United States the regulatory review is underway with the FDA to expand the use of CASGEVY to younger children after Vertex was awarded the Commissioner’s National Priority Voucher. Vertex has also recently completed regulatory submissions in the Kingdom of Saudi Arabia and United Kingdom to expand the use of CASGEVY to younger children. Upon availability, there is an established network of activated authorized treatment centers in these countries prepared to support patients. The use of CASGEVY in children ages 5–11 years is investigational. CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown in clinical trials to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. The completed Phase 1/2/3 open-label studies, CLIMB-111 and CLIMB-121, were designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12–35 years with TDT or with SCD and recurrent VOCs. Patients were followed for approximately two years after CASGEVY infusion in these studies. CLIMB-141 and CLIMB-151 are ongoing Phase 3 open-label studies, designed to assess the safety and efficacy of a single dose of exagamglogene autotemcel in patients ages 2–11 years with TDT or with SCD and recurrent VOCs. Enrollment and dosing are complete for the 5–11-year-old cohort in both studies. Each patient in these studies is asked to participate in the ongoing long-term, open-label study, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients with up to 15 years of follow-up after CASGEVY infusion. CASGEVY is a one-time therapy used to treat people ages 12 years and older with sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs and beta thalassemia (ß-thalassemia) who need regular blood transfusions. CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia. After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). The doctor will tell you when blood cell levels return to safe levels. You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Your healthcare provider may give you other medicines to treat your side effects. Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment. Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis).

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions

Alnylam Expands RNAi Drug Access as GENESIS Pharma Partnership Reaches Nordic Countries

Beone Medicines AG Approves Board and Committee Elections

Consensus revenue estimates decrease by 17%

Tango Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $600.000027 million.

Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors

Incyte to Acquire Vega Therapeutics for Up to US$2b Expanding Hematology Pipeline

TG Therapeutics Lifts Outlook as Subcutaneous Briumvi Shows Promise in MS and Myasthenia Gravis Trials

Amgen Shares Gain as Repatha Shows 29% Cardiovascular Event Reduction in Diabetes Trial

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality

Moderna Reports Strong Five-Year Melanoma Vaccine Data and Expands Ebola Program with CEPI Funding

Revolution Medicines Reports Daraxonrasib More Than Doubles Survival in Advanced Pancreatic Cancer Trial

Summit Therapeutics Advances Ivonescimab to Phase III After 70.8% Response in Colorectal Cancer

CEO & Director notifies of intention to sell stock

ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing